Navigation Links
BU researcher receives highest honor from the National Birth Defects Prevention Network
Date:2/27/2013

Boston, MAAllen A. Mitchell, MD, a professor of public health (epidemiology) and professor of pediatrics at the Boston University Schools of Public Health and Medicine, recently received the Godfrey P. Oakley, Jr., Award at the annual meeting of the National Birth Defects Prevention Network. Mitchell, who is also the director of Boston University's Slone Epidemiology Center (SEC), was recognized for his significant lifetime contributions to the field of birth defects.

Mitchell's interest in birth defects began as an undergraduate student and continued during his pediatric training. In 1967 he began work at the Boston Collaborative Drug Surveillance Program where he developed his focus on drug epidemiology (now called pharmacoepidemiology); among other activities, he worked on the analysis of Collaborative Perinatal Project data on birth defects and drugs in pregnancy.

In 1975 he joined the newly-created Drug Epidemiology Unit (now SEC) at Boston University, where following his interest in both pharmacoepidemiology and birth defects, Mitchell in 1975 applied the concept of case-control surveillance to the study of medications that may cause birth defects, and initiated the SEC Birth Defects Study (BDS) which continues to this time, having collected data on prenatal exposures for more than 40,000 malformed infants (and non-malformed infants) identified at multiple hospitals in the regions surrounding Boston, Philadelphia, Toronto, San Diego and most recently Nashville, as well as through birth defects registries in Massachusetts and New York state.

The BDS is now one of two data collection components collaborating with the American Academy of Allergy, Asthma, and Immunology in a national systematic surveillance effort (Vaccines and Medication in Pregnancy Safety Surveillance"VAMPSS") designed to evaluate the risks and safety of the wide range of medications taken by pregnant women. Mitchell also designed and directed epidemiologic efforts to evaluate pregnancy prevention efforts for drugs known to cause birth defects, including isotretinoin (Accutane and others) and thalidomide (Thalomid).

Mitchell is the author of numerous publications in the fields of birth defects pharmacoepidemiology and serves on many editorial boards and advisory committees. He obtained his undergraduate degree from Washington University in St. Louis in 1966 and his medical degree from Tufts University School of Medicine in Boston in 1970. He performed his pediatric residency training at the Boston Floating Hospital for Infants and Children (Tufts-New England Medical Center).

With this prestigious award the National Birth Defects Prevention Network honors Dr. Oakley who was instrumental in setting the birth defects agenda at the Centers for Disease Control and Prevention for many decades and in focusing national attention on the effects of folic acid in preventing neural tube defects.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
4. U of Alberta researcher steps closer to understand autoimmune diseases
5. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
6. UNH researchers find African farmers need better climate change data to improve farming practices
7. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
8. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
9. Researchers print live cells with a standard inkjet printer
10. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
11. Researchers reveal how a single gene mutation leads to uncontrolled obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology: